Recruiting

miR-342-5p/AnkG Pathway-Mediated Axon Initial Segment Filtering Injury and Early Synaptic Dysfunction in Alzheimer's Disease: Biomarker Exploration

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Collect peripheral blood, and if the patient consents, also collect cerebrospinal fluid.

Other
Who is being recruted

Alzheimer Disease+6

+ Mental Disorders

+ Brain Diseases

Over 50 Years
+15 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Diagnostic Study

Interventional
Study Start: June 2025
See protocol details

Summary

Principal SponsorThe Fourth Affiliated Hospital of Zhejiang University School of Medicine
Study ContactXu-hua Xu
Last updated: January 21, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: June 20, 2025

Actual date on which the first participant was enrolled.

Alzheimer's disease is a common condition that affects memory and cognitive abilities, particularly in older adults. The cause behind the early abnormalities in synaptic connections between brain cells in Alzheimer's is still unclear. Previous research suggests that certain substances, known as the miR-342-5p/AnkG-mediated pathway, might play a role in these abnormalities. These substances can be found in both blood and cerebrospinal fluid. This study aims to delve deeper into understanding the specific mechanisms behind these abnormal connections. The goal is to identify biomarkers for early detection of Alzheimer's, which could potentially pave the way for improved diagnosis in the future.

Official TitleEffects of miR-342-5p/AnkG Pathway-Mediated Axon Initial Segment Filtering Injury on Early Synaptic Dysfunction in Alzheimer's Disease and Its Clinical Applications 
NCT07353502
Principal SponsorThe Fourth Affiliated Hospital of Zhejiang University School of Medicine
Study ContactXu-hua Xu
Last updated: January 21, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

40 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Diagnostic Study

Diagnostic studies focus on improving how we detect or confirm a disease. They test new tools or techniques that could provide faster or more accurate diagnoses.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 50 Years

Range of ages for which participants are eligible to join.

Healthy volunteers allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Alzheimer DiseaseMental DisordersBrain DiseasesCentral Nervous System DiseasesDementiaNervous System DiseasesNeurodegenerative DiseasesNeurocognitive DisordersTauopathies

Criteria

8 inclusion criteria required to participate
Meet the diagnostic criteria for "probable AD dementia" established by the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA)
MMSE score between 0-23 points, Clinical Dementia Rating (CDR) score ≥0.5 points, Hachinski Ischemic Score <4 points
Brain MRI showing bilateral temporal lobe and hippocampal atrophy
Age ≥50 years
Show More Criteria
7 exclusion criteria prevent from participating
Dementia or cognitive impairment caused by other diseases
History of substance abuse
Progressive primary aphasia
Previous traumatic brain injury
Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups

2 intervention groups are designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental
Alzheimer's disease patients, collect peripheral blood, and if the patient agrees, also collect cerebrospinal fluid.

Group II

Healthy control, collect peripheral blood, and if the patient agrees, also collect cerebrospinal fluid.

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Recruiting

The Fourth Affiliated Hospital of Zhejiang University School of Medicine

Yiwu, ChinaSee the location
Recruiting
One Study Center